502U83: an arylmethylaminopropanediol; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 125301 |
| SCHEMBL ID | 10488246 |
| MeSH ID | M0182550 |
| Synonym |
|---|
| bw 502u83 |
| 2-[[10-(2-hydroxyethoxy)anthracen-9-yl]methylamino]-2-methylpropane-1,3-diol |
| unii-ic3b582lt1 |
| 129026-48-8 |
| 1,3-propanediol, 2-(((10-(2-hydroxyethoxy)-9-anthracenyl)methyl)amino)-2-methyl- |
| 502u83 |
| ic3b582lt1 , |
| SCHEMBL10488246 |
| DTXSID50156041 |
| bw-502u83 |
| bw-a502u |
| 502u83; bw a502u |
| 2-(((10-(2-hydroxyethoxy)-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol |
502U83 is an arylmethylaminopropanediol derivative exhibiting significant antineoplastic activity in a number of murine and human tumor models.
| Excerpt | Reference | Relevance |
|---|---|---|
| "502U83 is an arylmethylaminopropanediol that displays significant antitumor activity in a number of murine and human tumor-model systems. " | ( Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Clendeninn, NJ; Hohneker, JA; Janisch, L; Lucas, VS; Ratain, MJ; Ravitch, J; Schilsky, RL; Tuttle, RL; Vogelzang, NJ, 1993) | 1.99 |
| "502U83 is an arylmethylaminopropanediol derivative exhibiting significant antineoplastic activity in a number of murine and human tumor models. " | ( Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule. Bair, KW; Brown, TD; Havlin, KA; Kuhn, JG; Langevin, AM; Lucas, VS; Purvis, J; Turner, JN; Von Hoff, DD; Weiss, GR, 1990) | 1.98 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "28 hr, indicating rapid absorption of the compound; the bioavailability was estimated to be 62%." | ( Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83. Hinton, ML; Johnson, RL; Lewis, RP; Patel, DK; Schroeder, DH; Shockcor, JP; Sigel, CW, ) | 0.37 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Autoradiographs of rats dosed intravenously with [14C]502U83 showed the presence of significant levels of radioactivity in the bone marrow, salivary gland, thymus, and lung; highest levels were in the gastrointestinal tract." | ( Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83. Hinton, ML; Johnson, RL; Lewis, RP; Patel, DK; Schroeder, DH; Shockcor, JP; Sigel, CW, ) | 0.62 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (40.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (20.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (40.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||